There have been 258 placebo-controlled clinical trials of vaccines, according to a new research project. More than half of ...

Artificial blood could reduce preventable deaths in settings where limited supply costs millions of lives in low-income ...

Elon Musk’s Neuralink isn’t the only contender in the brain-tech race. Paradromics has entered the arena with its first human brain-computer interface (BCI) implant. The neurotechnology startup on ...

Almost a year after it welcomed its first patient for trial, Elon Musk's neurotechnology company Neuralink has recently ...

Test your knowledge of immunisation and clinical trials with this Higher Human Biology quiz in preparation of your Higher Human Biology exam.

While all groups have demonstrated an inspiring level of dedication and passion, I have always been moved by patients’ ...

ExoPTEN is being developed as a first-in-class, exosome-based therapy targeting high-impact neurological indications, including acute spinal cord injury, optic nerve damage, facial nerve injury, and ...

Neuralink accelerates its brain-computer interface ambitions with a major funding boost and ongoing human trials.

Phase 2 data expected in 2H 2026 - - KPL-387 Phase 1 single ascending dose data support profile for monthly dosing - LONDON, ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

Maxiom Labs, Inc. (MAXIOM) officially launched its revolutionary AI platform designed to optimize health, fitness, and performance-for committed athletes and everyday achievers alike. After months of ...

Elon Musk’s brain-computer interface company, Neuralink, has secured $650 million in a fresh funding round as it moves ahead with ...